Influenza Vaccine – CSL V118_24

This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV). The aim of the study is to evaluate MF59-adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccine in the prevention of reverse transcription-polymerase chain reaction (RT-PCR).

Inclusion Criteria:

In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.

  • Adults of ≥65 years of age on the day of vaccination
  • Individuals who have voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry
  • Individuals who have the ability to comply with study procedures including follow-up
  • Other criteria may apply

Complete the form and our team will reach out soon to help determine your eligibility.

View Study on ClinicalTrials.gov

Trial Interest Form

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
Consent(Required)

Locations

Clarkston Medical Group

5701 Bow Pointe Drive
Suites 100 & 105
Clarkston, Michigan